Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

@article{PujadeLauraine2010PegylatedLD,
  title={Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.},
  author={{\'E}. Pujade-Lauraine and U. Wagner and E. Aavall-Lundqvist and V. Gebski and M. Heywood and P. Vasey and B. Volgger and I. Vergote and S. Pignata and A. Ferrero and J. Sehouli and A. Lortholary and G. Kristensen and C. Jackisch and F. Joly and C. Brown and N. Le Fur and A. Du Bois},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 20},
  pages={
          3323-9
        }
}
PURPOSE This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC). PATIENTS AND METHODS Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based… Expand
438 Citations

Paper Mentions

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
  • S. Pignata, G. Scambia, +27 authors F. Perrone
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
  • 144
Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer.
  • 4
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
  • 225
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
  • 456
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
  • 142
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
  • 929
  • PDF
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
  • 1,086
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
  • R. Ozols, B. Bundy, +7 authors R. Baergen
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
  • 1,767
...
1
2
3
4
5
...